Assessing the effectiveness of oxybutynin and phenazopyridine and celecoxib in reducing complications in the treatment of bladder tumors.
Phase 3
- Conditions
- Malignant neoplasm of bladder.Malignant neoplasm of bladder
- Registration Number
- IRCT20171225038070N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
bladder cancer
candidates for BCG therapy
Non muscle bladder cancer
Exclusion Criteria
history of pelvic surgery
severe urinary tract symptoms (IPSS over 20)
overactive bladder
complete urinary incontinence
traumatic catheterization
active TB symptoms
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency. Timepoint: Six consecutive weeks at the same time as the induction treatment period for BCG.The days of 0, 7,14,21,28,35 of the intervention. Method of measurement: Ask the patient and register in the questionnaire.
- Secondary Outcome Measures
Name Time Method